Prestige BioPharma

At a glance

Prestige BioPharma filed 51 disclosures in the last 12 months, including 7 insider, 7 5% holder and 1 contract. The most recent key filing was on Sep 1: An insider bought 4,800 sh on the market at an average ₩6,241, Aug 25–28.

Revenue for 2025 was ₩10.2M, up 1875.4% on 2024. It made an operating loss of ₩48M. Debt was 47% of equity at year end.

The 2025 annual report lists 67 employees with an average tenure of 1.9 years and average pay of ₩53.6M, #1523 of 2,191 listed companies by average pay. Its 9 directors and auditors were paid ₩194.6M each on average. It paid no cash dividend for 2025. Mayson Partners Pte. Ltd. and related parties held 52.04% at year end.

Of 5 recent 5%+ holder reports, 5 raised and 0 cut a stake; the largest stake reported was 52.50% on Sep 1.

From the 2025 annual report

Staff: 67 (18 men, 49 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩3.6B. Directors and auditors: 9, paid ₩1.8B in total.

No cash dividend was paid for 2025.

Largest shareholder

Mayson Partners Pte. Ltd. holds 21.65%; with 4 related parties the group holds 52.04% of common shares at year end.

Individuals paid ₩500M or more

Source: 2025 annual business report (DART). How figures are combined

New contracts, last 12 months

1 new supply contract worth 13% of the revenue stated in the filings.

Amended amounts replace the originals. Subsidiary contracts and terminations are excluded.

Financial summary

5%+ holder reports